Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI, Choueiri TK.

Cancer. 2011 Jun 15;117(12):2637-42. doi: 10.1002/cncr.25750. Epub 2010 Nov 18.

2.

Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps.

Kedika R, Patel M, Pena Sahdala HN, Mahgoub A, Cipher D, Siddiqui AA.

J Clin Gastroenterol. 2011 Feb;45(2):e12-6. doi: 10.1097/MCG.0b013e3181ea1044.

PMID:
20697294
3.

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ.

Ann Oncol. 2011 Feb;22(2):295-300. doi: 10.1093/annonc/mdq342. Epub 2010 Jul 25.

PMID:
20657034
4.

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V.

J Clin Oncol. 2010 May 1;28(13):2144-50. doi: 10.1200/JCO.2009.26.7849. Epub 2010 Apr 5.

PMID:
20368553
5.

Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells.

Gong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA.

Pancreas. 2010 Jul;39(5):581-94. doi: 10.1097/MPA.0b013e3181c314cd.

PMID:
20118823
6.

The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.

Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK.

Gut. 2010 May;59(5):630-7. doi: 10.1136/gut.2009.188961. Epub 2009 Nov 1.

PMID:
19880966
7.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK.

J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.

PMID:
19826129
8.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R.

Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15.

PMID:
19615940
9.

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.

Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E.

J Cancer Res Clin Oncol. 2009 Oct;135(10):1429-35. doi: 10.1007/s00432-009-0587-3. Epub 2009 Apr 28.

PMID:
19399518
10.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.

Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

PMID:
19097774
11.

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW.

Cancer. 2008 Oct 1;113(7):1552-8. doi: 10.1002/cncr.23776.

12.

The renin-angiotensin system and malignancy.

Ager EI, Neo J, Christophi C.

Carcinogenesis. 2008 Sep;29(9):1675-84. doi: 10.1093/carcin/bgn171. Epub 2008 Jul 16. Review.

PMID:
18632755
13.

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B.

J Clin Oncol. 2008 Jan 1;26(1):127-31. doi: 10.1200/JCO.2007.13.3223.

PMID:
18165647
14.

Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases.

Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C.

J Gastroenterol Hepatol. 2007 Apr;22(4):577-84.

PMID:
17376054
15.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.

N Engl J Med. 2007 Jan 11;356(2):115-24.

16.

Manipulating the angiotensin system--new approaches to the treatment of solid tumours.

Ino K, Shibata K, Kajiyama H, Nawa A, Nomura S, Kikkawa F.

Expert Opin Biol Ther. 2006 Mar;6(3):243-55. Review.

PMID:
16503734
17.

Novel approaches in the therapy of metastatic renal cell carcinoma.

Lam JS, Leppert JT, Belldegrun AS, Figlin RA.

World J Urol. 2005 Jul;23(3):202-12. Epub 2005 Apr 5. Review.

PMID:
15812574
18.

Global cancer statistics, 2002.

Parkin DM, Bray F, Ferlay J, Pisani P.

CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.

19.

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

Janzen NK, Kim HL, Figlin RA, Belldegrun AS.

Urol Clin North Am. 2003 Nov;30(4):843-52. Review.

PMID:
14680319
20.

Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells.

Muscella A, Greco S, Elia MG, Storelli C, Marsigliante S.

J Endocrinol. 2002 May;173(2):315-23.

Supplemental Content

Support Center